THE PROGNOSTIC-SIGNIFICANCE OF CA-125 HALF-LIFE IN PATIENTS WITH OVARIAN-CANCER WHO HAVE RECEIVED PRIMARY CHEMOTHERAPY AFTER SURGICAL CYTOREDUCTION

被引：59

作者：

HUNTER, VJ

DALY, L

HELMS, M

SOPER, JT

BERCHUCK, A

CLARKEPEARSON, DL

BAST, RC

机构：

[1] DUKE UNIV,MED CTR,DEPT HORT SCI & LANDSCAPE ARCHITECTURE,BOX 3843,DURHAM,NC 27710

[2] DUKE UNIV,MED CTR,DEPT COMMUNITY & FAMILY MED,DURHAM,NC 27710

[3] DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710

[4] DUKE UNIV,MED CTR,DEPT MICROBIOL IMMUNOL,DURHAM,NC 27710

[5] DUKE UNIV,MED CTR,DUKE COMPREHENS CANC CTR,DURHAM,NC 27710

来源：

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY | 1990年 / 163卷 / 04期

关键词：

CA; 125; half-life; ovarian cancer; prognosis;

D O I：

10.1016/0002-9378(90)90680-6

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Fifty-four patients with advanced epithelial ovarian cancer were monitored with serial serum CA 125 levels after surgical cytoreduction and during multi-agent chemotherapy with cisplatin-containing regimens. CA 125 half-life of <20 days was associated with prolonged overall survival (p < 0.015). In those patients who eventually were found to be disease-free at surgical surveillance procedures, normalization of serum CA 125 levels to <35 U/ml within 65 days of primary operation also suggested an improved survival (p < 0.059). © 1990.

引用

页码：1164 / 1167

页数：4

共 9 条

[1] A RADIOIMMUNOASSAY USING A MONOCLONAL-ANTIBODY TO MONITOR THE COURSE OF EPITHELIAL OVARIAN-CANCER
BAST, RC
KLUG, TL
STJOHN, E
JENISON, E
NILOFF, JM
LAZARUS, H
BERKOWITZ, RS
LEAVITT, T
GRIFFITHS, CT
PARKER, L
ZURAWSKI, VR
KNAPP, RC
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (15) : 883 - 887
[2] CA-125 SERUM LEVELS CORRELATED WITH 2ND-LOOK OPERATIONS AMONG OVARIAN-CANCER PATIENTS
BEREK, JS
KNAPP, RC
MALKASIAN, GD
LAVIN, PT
WHITNEY, C
NILOFF, JM
BAST, RC
[J]. OBSTETRICS AND GYNECOLOGY, 1986, 67 (05) : 685 - 689
[3] OVARIAN-CANCER ANTIGEN CA125 - A PROSPECTIVE CLINICAL-ASSESSMENT OF ITS ROLE AS A TUMOR-MARKER
CANNEY, PA
MOORE, M
WILKINSON, PM
JAMES, RD
[J]. BRITISH JOURNAL OF CANCER, 1984, 50 (06) : 765 - 769
[4] JACOBS I, 1989, HUM REPROD, V4, P1
[5] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS
KAPLAN, EL
MEIER, P
[J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) : 457 - 481
[6] LAVIN PT, 1987, OBSTET GYNECOL, V69, P223
[7] USE OF CA-125 TO PREDICT SURVIVAL OF PATIENTS WITH OVARIAN-CARCINOMA
RUSTIN, GJS
GENNINGS, JN
NELSTROP, AE
COVARRUBIAS, H
LAMBERT, HE
BAGSHAWE, KD
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) : 1667 - 1671
[8] SHPALL EJ, IN PRESS GYNECOL ONC
[9] OVARIAN-CANCER - THE PROGNOSTIC VALUE OF THE SERUM HALF-LIFE OF CA125 DURING INDUCTION CHEMOTHERAPY
VANDERBURG, MEL
LAMMES, FB
VANPUTTEN, WLJ
STOTER, G
[J]. GYNECOLOGIC ONCOLOGY, 1988, 30 (03) : 307 - 312

← 1 →